Group 1 - The core point of the article highlights the financing activities of Huaren Health, indicating a net buying trend in recent trading days [1] - On August 5, Huaren Health had a financing buy amount of 0.17 billion, ranking 1896th in the market, with a financing repayment amount of 0.13 billion, resulting in a net purchase of 3.8777 million [1] - Over the last three trading days (August 1-5), Huaren Health received financing buys of 0.40 billion, 0.22 billion, and 0.17 billion respectively [1] Group 2 - In terms of securities lending, on the same day, there were no shares sold or net sold, indicating no activity in this area [2]

安徽华人健康医药股份有限公司 简式权益变动报告书 上市公司名称：安徽华人健康医药股份有限公司 股票上市地点：深圳证券交易所 股票简称：华人健康 股票代码：301408 信息披露义务人 1：何家乐 住所：安徽省合肥市 通讯地址：安徽省合肥市包河区上海路 18 号华人健康大厦 6 楼 信息披露义务人 2：何家伦 住所：安徽省合肥市 通讯地址：安徽省合肥市包河区上海路 18 号华人健康大厦 4 楼 信息披露义务人 3：合肥时达股权投资合伙企业（有限合伙） 住所：合肥市包河经济开发区上海路 18 号 3 号标准厂房 B 幢 6 楼 通讯地址：安徽省合肥市包河区上海路 18 号华人健康大厦 605 室 1、本报告书系信息披露义务人依据《中华人民共和国证券法》《上市公司 收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权 益变动报告书》及其他相关的法律、法规编写。 2、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人合伙协议或内部规则中的任何条款，或与之相冲突。 信息披露义务人 4：宁波梅山保税港区胜凡投资合伙企业（有限合伙） 住所：浙江省宁波市北仑区梅山七星路 8 ...

告 证券代码：301408 证券简称：华人健康 公告编号：2025-056 安徽华人健康医药股份有限公司 关于股东解除一致行动关系暨权益变动的提示性公 何家乐先生是公司实际控制人、董事长、总裁，在公司首次公开发行股票并 上市时，其作为员工持股平台的普通合伙人暨执行事务合伙人，实际控制员工持 股平台所持有公司股份的表决权，员工持股平台为何家乐先生的一致行动人。在 一致行动关系存续期间，各方在公司重大事项的决策上始终保持一致意见，严格 履行相关承诺事项，不存在滥用自身控制地位的情形。 二、一致行动关系解除情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除一致行动关系是公司股东的普通合伙人暨执行事务合伙人发生 变更所致，不涉及各股东持股数量变动； 2、本次权益变动不会导致公司控股股东、实际控制人发生变化，亦不触及 要约收购。 安徽华人健康医药股份有限公司（以下简称"公司"）于近日收到股东宁波 梅山保税港区胜凡投资合伙企业（有限合伙）（以下简称"胜凡投资"）、宁波 梅山保税港区福曼医投资合伙企业（有限合伙）（以下简称"福曼医投资"）、 合肥 ...

Group 1 - The core viewpoint of the article highlights the financial performance and market activity of Huaren Health (301408) as of August 1, 2025, with a closing price of 15.02 yuan, reflecting a 0.94% increase [1] - The company reported total revenue of 1.267 billion yuan for Q1 2025, representing a year-on-year growth of 14.71%, and a net profit attributable to shareholders of 61.22 million yuan, up 28.15% year-on-year [1] - The company has a current ratio of 1.189, a quick ratio of 0.786, and a debt-to-asset ratio of 57.07%, indicating its liquidity and financial stability [1] Group 2 - Huaren Health has made investments in 18 companies and participated in 33 bidding projects, showcasing its active engagement in business expansion [2] - The company holds 156 trademark registrations and 21 patents, reflecting its focus on intellectual property and innovation [2] - Additionally, Huaren Health possesses 41 administrative licenses, indicating its compliance and operational capabilities within the industry [2]

Core Insights - The stock of Huaren Health experienced a decline of 0.87% on July 31, with a trading volume of 313 million yuan [1] - The company reported a financing buy-in amount of 22.32 million yuan and a net financing buy of 698,200 yuan on the same day [1] - As of July 31, the total financing and securities lending balance for Huaren Health was 139 million yuan, representing 6.26% of its market capitalization [1] Financing and Securities Lending - On July 31, Huaren Health had a financing buy-in of 22.32 million yuan, with a current financing balance of 139 million yuan, which is above the 90th percentile of the past year [1] - The securities lending data showed that on July 31, there were no shares sold short, and the securities lending balance was also zero, indicating a low level of short selling activity [1] Company Overview - Huaren Health, established on June 29, 2001, is located in Hefei, Anhui Province, and was listed on March 1, 2023 [1] - The company's main business segments include pharmaceutical agency, retail, and terminal procurement, with the revenue composition being 80.25% from Western and Chinese medicines, 4.62% from health products, and 4.00% from medical devices [1] Financial Performance - For the period from January to March 2025, Huaren Health achieved a revenue of 1.267 billion yuan, reflecting a year-on-year growth of 14.71% [2] - The net profit attributable to the parent company for the same period was 61.22 million yuan, representing a year-on-year increase of 28.15% [2] Shareholder Information - As of March 31, 2025, the number of shareholders for Huaren Health increased by 9.39% to 18,000, while the average circulating shares per person decreased by 8.58% to 8,309 shares [2] - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [3] - Notably, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders as of March 31, 2025 [3]

本文源自：金融界 最近三个交易日，29日-31日，华人健康分别获融资买入0.17亿元、0.53亿元、0.22亿元。 融券方面，当日融券卖出0.00万股，净买入0.01万股。 7月31日，沪深两融数据显示，华人健康获融资买入额0.22亿元，居两市第1770位，当日融资偿还额0.22 亿元，净买入69.82万元。 作者：智投君 ...

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 本文源自：金融界 作者：智投君 7月30日，沪深两融数据显示，华人健康获融资买入额0.53亿元，居两市第893位，当日融资偿还额0.52 亿元，净买入61.72万元。 最近三个交易日，28日-30日，华人健康分别获融资买入0.24亿元、0.17亿元、0.53亿元。 ...

7月30日，华人健康今日收盘15.01元，上涨5.48%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到39.72倍，创22天以来新低，总市值60.04亿元。 从行业市盈率排名来看，公司所处的医药商业行业市盈率平均44.76倍，行业中值30.23倍，华人健康排 名第22位。 截至2025年一季报，共有2家机构持仓华人健康，其中基金2家，合计持股数0.77万股，持股市值0.00亿 元。 安徽华人健康医药股份有限公司的主营业务是医药零售、代理及终端集采业务。公司的主要产品是中西 成药、中药饮片、保健品、医疗器械、特色原料药等。2024年度，公司营业收入再创新高，达45.32亿 元，比上年同期增长19.34%；归属于母公司所有者的净利润为1.38亿元，比上年同期增长20.09%；归属 于母公司所有者的扣除非经常性损益净利润1.29亿元，比上年同期增长21.81%，其中研发费用为 2,938.73万元，比上年同期增长21.46%。公司经营性现金流量持续改善，经营质量稳步提升。 作者：行情君 最新一期业绩显示，2025年一季报，公司实现营业收入12.67亿元，同比14.71%；净利润6122.23万元， ...

Group 1 - The stock price of Huaren Health closed at 15.01 yuan on July 30, an increase of 0.78 yuan from the previous trading day [1] - The opening price on the same day was 14.21 yuan, with a highest point of 15.83 yuan and a lowest point of 14.13 yuan, resulting in an intraday volatility of 11.95% [1] - The trading volume was 334,074 hands, with a total transaction amount of 499 million yuan [1] Group 2 - Huaren Health operates in the pharmaceutical commercial sector, with main businesses including pharmaceutical retail chains, wholesale, and logistics distribution [1] - The company is headquartered in Anhui and its business scope covers multiple regions across the country [1] - During intraday trading on July 30, Huaren Health experienced a rapid pullback, with a drop of over 2% within 5 minutes, and a transaction amount of 314 million yuan at that time [1] - The net inflow of main funds on that day was 21.02 million yuan [1]

天眼查商业履历信息显示，安徽华人健康医药股份有限公司，成立于2001年，位于合肥市，是一家以从 事零售业为主的企业。企业注册资本40001万人民币，实缴资本3888.89万人民币。公司法定代表人为何 家乐。 通过天眼查大数据分析，安徽华人健康医药股份有限公司共对外投资了18家企业，参与招投标项目33 次，知识产权方面有商标信息156条，专利信息21条，此外企业还拥有行政许可41个。 来源：金融界 金融界消息 截至2025年7月30日收盘，华人健康（301408）报收于15.01元，上涨5.48%，换手率 22.4%，成交量33.41万手，成交金额4.99亿元。 资金流向方面，今日主力资金净流入2101.58万元，占比成交额4.21%。其中，超大单净流入3121.25万 元、占成交额6.26%，大单净流出1019.67万元、占成交额2.04%，中单净流出流出2648.56万元、占成交 额5.31%，小单净流入546.98万元、占成交额1.1%。 华人健康最新一期业绩显示，截至2025一季报，公司营业总收入12.67亿元、同比增长14.71%，归属净 利润6122.23万元，同比增长28.15%，扣非净利润597 ...